{"analyses":[{"ciLowerLimit":"1.16","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"19.76","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in event-free rates","paramValue":"10.46"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.69","upperLimit":"59.61","value":"53.15"},{"groupId":"OG001","lowerLimit":"36.00","upperLimit":"49.38","value":"42.69"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"description":"DFS rate was defined as percentage of participants who were disease-free at Year 5. DFS rate was analyzed in PD-L1 subpopulation within the Stage II-IIIA population. The DFS rate was estimated by the Kaplan-Meier methodology for each treatment arm. Percentages have been rounded off to the nearest decimal.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.","id":"OG000","title":"Atezolizumab"},{"description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received no treatment in the randomization phase BSC arm.","id":"OG001","title":"Best Supportive Care (BSC)"}],"paramType":"NUMBER","populationDescription":"PD-L1 subpopulation, defined as ≥ 1% TC expression by the SP263 IHC assay, included Stage II-IIIA population with valid PD-L1 SP263 measurement at baseline. Stage II-IIIA population included all randomized participants with extent of disease as either Stage II or Stage III, \\& is a subset of ITT population. Randomized ITT population included all randomized participants with resected Stage IB (tumors ≥ 4 cm)-IIIA NSCLC whether the participant received the assigned treatment.","reportingStatus":"POSTED","timeFrame":"Year 5","title":"Disease-free Rate at Year 5 in PD-L1 (SP263 ≥ 1% TC) Subpopulation Within the Stage II-IIIA Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}